{"id":"arsi","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"ARSI targets the androgen receptor pathway, which is critical for the growth and survival of androgen-dependent malignancies such as prostate cancer. By inhibiting androgen receptor signaling, the drug aims to prevent cancer cell proliferation and induce apoptosis in hormone-sensitive tumors. This mechanism is particularly relevant in castration-resistant prostate cancer and other AR-driven malignancies.","oneSentence":"ARSI is an androgen receptor signaling inhibitor that blocks androgen receptor activity to suppress hormone-dependent cancer cell growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:57:15.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Castration-resistant prostate cancer"},{"name":"Androgen receptor-driven malignancies"}]},"trialDetails":[{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT05997615","phase":"PHASE1","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer","status":"RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2023-08-10","conditions":"Hormone-refractory Prostate Cancer","enrollment":390},{"nctId":"NCT06836726","phase":"PHASE2","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-05-27","conditions":"Castration Resistant Prostate Cancer","enrollment":35},{"nctId":"NCT07210086","phase":"PHASE2","title":"Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-11-26","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT07260435","phase":"PHASE3","title":"Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Nick Beije","startDate":"2024-02-20","conditions":"Prostate Cancer","enrollment":400},{"nctId":"NCT06200558","phase":"","title":"ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa","status":"RECRUITING","sponsor":"Hospital of Macerata","startDate":"2024-01-31","conditions":"Prostate Cancer","enrollment":534},{"nctId":"NCT06150417","phase":"PHASE2","title":"MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-07-01","conditions":"Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate","enrollment":200},{"nctId":"NCT06844383","phase":"PHASE2","title":"A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate","status":"RECRUITING","sponsor":"Prostate Cancer Clinical Trials Consortium","startDate":"2025-10","conditions":"Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":126},{"nctId":"NCT06141993","phase":"","title":"ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials","status":"RECRUITING","sponsor":"Duke University","startDate":"2024-05-13","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic","enrollment":120},{"nctId":"NCT06392295","phase":"PHASE2","title":"PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-07-03","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer","enrollment":34},{"nctId":"NCT03725761","phase":"PHASE2","title":"Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2018-10-24","conditions":"Prostate Cancer","enrollment":31},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT06429813","phase":"NA","title":"Remotely Monitored Exercise Interventions in Patients with MCSPC Undergoing ADT (Prostate 006)","status":"RECRUITING","sponsor":"Paul Viscuse","startDate":"2024-07-26","conditions":"Castrate Sensitive Prostate Cancer, Metastatic Prostate Cancer","enrollment":24},{"nctId":"NCT05612880","phase":"","title":"Physical Function During ARSI Treatment","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-10-13","conditions":"Advanced Prostate Carcinoma","enrollment":24},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT04067713","phase":"","title":"Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-09-20","conditions":"Metastatic Prostate Cancer","enrollment":192},{"nctId":"NCT04279561","phase":"PHASE1","title":"Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-04-16","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":580,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARSI","genericName":"ARSI","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARSI is an androgen receptor signaling inhibitor that blocks androgen receptor activity to suppress hormone-dependent cancer cell growth. Used for Castration-resistant prostate cancer, Androgen receptor-driven malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}